Alosetron (original) (raw)
Alosetron, sold under the brand name Lotronex among others, is a 5-HT3 antagonist used for the management of severe diarrhea-predominant irritable bowel syndrome (IBS) in women only. It was patented in 1987 and approved for medical use in 2002. It is currently marketed by Prometheus Laboratories Inc. (San Diego). Alosetron was withdrawn from the market in 2000 owing to the occurrence of serious life-threatening gastrointestinal adverse effects, but was reintroduced in 2002 with availability and use restricted.
| Property | Value |
|---|---|
| dbo:abstract | Alosetron, sold under the brand name Lotronex among others, is a 5-HT3 antagonist used for the management of severe diarrhea-predominant irritable bowel syndrome (IBS) in women only. It was patented in 1987 and approved for medical use in 2002. It is currently marketed by Prometheus Laboratories Inc. (San Diego). Alosetron was withdrawn from the market in 2000 owing to the occurrence of serious life-threatening gastrointestinal adverse effects, but was reintroduced in 2002 with availability and use restricted. (en) Alosetron (Handelsname: Lotronex® (USA); Hersteller: ) ist ein Arzneistoff aus der Gruppe der Setrone, der in den USA zur Behandlung des Reizdarmsyndroms eingesetzt wird. Der Wirkstoff wurde 1989 von Glaxo Wellcome als Ulcusmittel patentiert. Verwendet wird das Hydrochlorid. (de) L'alosétron est un antagoniste 5HT3 utilisé en cas de côlon irritable à prédominance de diarrhées sévères chez des femmes. Commercialisé par GlaxoSmithKline sous le nom commercial de Lotronex aux États-Unis, il n'est pas commercialisé en France, en Suisse et en Belgique au 17 juillet 2013. Aux États-Unis, il a été retiré du marché en 2000 en raison d'une toxicité gastro-intestinale sévère menaçant le pronostic vital, mais a été réintroduit en 2002, avec une disponibilité et une utilisation restreintes. (fr) Alossetrona é um fármaco antagonista dos receptores 5-HT3 da serotonina, utilizado para tratamento da síndrome do cólon irritável (SCI), em mulheres. As doses utilizadas são de 1 mg, duas vezes ao dia. (pt) |
| dbo:alternativeName | Lotronex (en) |
| dbo:bioavailability | 50.000000 (xsd:float) |
| dbo:casNumber | 122852-42-0 |
| dbo:chEBI | 253342 |
| dbo:chEMBL | 1110 |
| dbo:drugbank | DB00969 |
| dbo:fdaUniiCode | 13Z9HTH115 |
| dbo:kegg | D07129 |
| dbo:medlinePlus | a601230 |
| dbo:pubchem | 2099 |
| dbo:thumbnail | wiki-commons:Special:FilePath/Alosetron.svg?width=300 |
| dbo:wikiPageID | 1167402 (xsd:integer) |
| dbo:wikiPageLength | 15981 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1102283133 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:California dbr:San_Diego,_California dbr:Enteric_nervous_system dbr:Death dbr:Richard_Horton_(editor) dbr:Ulcerative_colitis dbr:Postmarketing_surveillance dbc:GSK_plc_brands dbc:Imidazoles dbc:Lactams dbr:Crohn's_disease dbr:GlaxoSmithKline dbr:Constipation dbr:The_Lancet dbr:Stenosis dbr:Fecal_impaction dbr:Gastrointestinal dbc:Gamma-Carbolines dbr:Toxic_megacolon dbr:U.S._Food_and_Drug_Administration dbr:Diverticulitis dbr:Irritable_bowel_syndrome dbr:5-HT3_antagonist dbc:5-HT3_antagonists dbc:Pyridoindoles dbr:European_Union dbr:Fluvoxamine dbr:Center_for_Drug_Evaluation_and_Research dbr:Ischemic_colitis dbr:Tablet_(pharmacy) dbr:CYP1A2 dbr:CYP2C9 dbr:CYP3A4 dbr:Mesenteric_ischemia dbr:Ondansetron dbr:British_Medical_Journal dbr:Regulatory_capture dbr:Editor_in_chief dbr:Thrombophlebitis dbr:Ischaemia dbr:Ischaemic_colitis |
| dbp:atcPrefix | A03 (en) |
| dbp:atcSuffix | AE01 (en) |
| dbp:bioavailability | 50 (xsd:integer) |
| dbp:c | 17 (xsd:integer) |
| dbp:casNumber | 122852 (xsd:integer) |
| dbp:chebi | 253342 (xsd:integer) |
| dbp:chembl | 1110 (xsd:integer) |
| dbp:chemspiderid | 2015 (xsd:integer) |
| dbp:drugbank | DB00969 (en) |
| dbp:eliminationHalfLife | -6120.0 |
| dbp:excretion | Renal 73%, faecal 24% (en) |
| dbp:h | 18 (xsd:integer) |
| dbp:image | Alosetron ball-and-stick model.png (en) |
| dbp:iupacName | 5 (xsd:integer) |
| dbp:iupharLigand | 2296 (xsd:integer) |
| dbp:kegg | D07129 (en) |
| dbp:legalUs | Rx-only (en) |
| dbp:medlineplus | a601230 (en) |
| dbp:metabolism | Hepatic (en) |
| dbp:n | 4 (xsd:integer) |
| dbp:o | 1 (xsd:integer) |
| dbp:pregnancyUs | B (en) |
| dbp:proteinBound | 82.0 |
| dbp:pubchem | 2099 (xsd:integer) |
| dbp:routesOfAdministration | Oral (en) |
| dbp:smiles | Cc1nc[nH]c1CN2CCc4cc3ccccc3n4C (en) |
| dbp:stdinchi | 1 (xsd:integer) |
| dbp:stdinchikey | JSWZEAMFRNKZNL-UHFFFAOYSA-N (en) |
| dbp:tradename | Lotronex (en) |
| dbp:unii | 13 (xsd:integer) |
| dbp:verifiedrevid | 477318612 (xsd:integer) |
| dbp:width | 222 (xsd:integer) |
| dbp:wikiPageUsesTemplate | dbt:Drugbox dbt:Reflist dbt:Serotonergics dbt:Short_description dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Ebicite dbt:Fdacite dbt:Keggcite dbt:Stdinchicite dbt:Drugs_for_functional_gastrointestinal_disorders dbt:Drugs.com |
| dcterms:subject | dbc:GSK_plc_brands dbc:Imidazoles dbc:Lactams dbc:Gamma-Carbolines dbc:5-HT3_antagonists dbc:Pyridoindoles |
| gold:hypernym | dbr:Antagonist |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:WikicatAmides yago:WikicatMolecularFormulas yago:Abstraction100002137 yago:Amide114724264 yago:Base114618253 yago:Chemical114806838 yago:Communication100033020 yago:Compound114818238 yago:Formula106816935 yago:Imidazole114916670 yago:Material114580897 yago:Matter100020827 yago:Message106598915 yago:MolecularFormula106817173 yago:OrganicCompound114727670 yago:Part113809207 yago:PhysicalEntity100001930 yago:Relation100031921 yago:WikicatImidazoles dbo:Drug yago:Statement106722453 yago:Substance100019613 umbel-rc:DrugProduct |
| rdfs:comment | Alosetron, sold under the brand name Lotronex among others, is a 5-HT3 antagonist used for the management of severe diarrhea-predominant irritable bowel syndrome (IBS) in women only. It was patented in 1987 and approved for medical use in 2002. It is currently marketed by Prometheus Laboratories Inc. (San Diego). Alosetron was withdrawn from the market in 2000 owing to the occurrence of serious life-threatening gastrointestinal adverse effects, but was reintroduced in 2002 with availability and use restricted. (en) Alosetron (Handelsname: Lotronex® (USA); Hersteller: ) ist ein Arzneistoff aus der Gruppe der Setrone, der in den USA zur Behandlung des Reizdarmsyndroms eingesetzt wird. Der Wirkstoff wurde 1989 von Glaxo Wellcome als Ulcusmittel patentiert. Verwendet wird das Hydrochlorid. (de) L'alosétron est un antagoniste 5HT3 utilisé en cas de côlon irritable à prédominance de diarrhées sévères chez des femmes. Commercialisé par GlaxoSmithKline sous le nom commercial de Lotronex aux États-Unis, il n'est pas commercialisé en France, en Suisse et en Belgique au 17 juillet 2013. Aux États-Unis, il a été retiré du marché en 2000 en raison d'une toxicité gastro-intestinale sévère menaçant le pronostic vital, mais a été réintroduit en 2002, avec une disponibilité et une utilisation restreintes. (fr) Alossetrona é um fármaco antagonista dos receptores 5-HT3 da serotonina, utilizado para tratamento da síndrome do cólon irritável (SCI), em mulheres. As doses utilizadas são de 1 mg, duas vezes ao dia. (pt) |
| rdfs:label | Alosetron (de) Alosetron (en) Alosétron (fr) Alossetrona (pt) |
| owl:sameAs | freebase:Alosetron yago-res:Alosetron http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00969 http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2099 wikidata:Alosetron http://azb.dbpedia.org/resource/آلوسترون dbpedia-cy:Alosetron dbpedia-de:Alosetron dbpedia-fa:Alosetron dbpedia-fr:Alosetron dbpedia-hu:Alosetron http://or.dbpedia.org/resource/ଆଲୋସେଟ୍ରନ dbpedia-pt:Alosetron dbpedia-ro:Alosetron dbpedia-sh:Alosetron dbpedia-sr:Alosetron https://global.dbpedia.org/id/3rcqs |
| prov:wasDerivedFrom | wikipedia-en:Alosetron?oldid=1102283133&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/Alosetron.svg wiki-commons:Special:FilePath/Alosetron_ball-and-stick_model.png |
| foaf:isPrimaryTopicOf | wikipedia-en:Alosetron |
| is dbo:wikiPageRedirects of | dbr:Lotronex dbr:C17H18N4O dbr:ATC_code_A03AE01 dbr:ATCvet_code_QA03AE01 dbr:Alosetron_Hydrochloride dbr:Alosetron_hydrochloride |
| is dbo:wikiPageWikiLink of | dbr:Lotronex dbr:Eluxadoline dbr:GSK_plc dbr:C17H18N4O dbr:Drug_of_last_resort dbr:5-HT3_antagonist dbr:5-HT3_receptor dbr:5-HT_receptor dbr:ATC_code_A03AE01 dbr:ATCvet_code_QA03AE01 dbr:ATC_code_A03 dbr:CYP1A2 dbr:Natalizumab dbr:List_of_withdrawn_drugs dbr:Serotonin_receptor_antagonist dbr:List_of_drugs:_Al dbr:List_of_drugs:_Lo dbr:Alosetron_Hydrochloride dbr:Alosetron_hydrochloride |
| is foaf:primaryTopic of | wikipedia-en:Alosetron |
